MAP2K7 and melanoma: Amaria et al. conducted a randomized phase II study comparing perioperative doublet therapy with dabrafenib (a BRAF inhibitor) and trametinib (an MEK inhibitor) and surgery followed by adjuvant therapy in patients with stage III or resectable stage IV malignant melanoma with BRAF V600E/K mutation [32].